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It is more than 80 years since the first attempts were made to immunize human cancer 
patients against  their own tumors  (for review see reference 1).  As yet, there are no 
immunological manipulations  of proven value in  terms  of ensuring  long-term cure, 
though there are randomized control studies demonstrating short-term prolongation of 
survival in patients with acute myelogenous leukemia receiving bacille Calmette-Guerin 
(BCG) 1 with  or  without  aUogeneic leukemic blasts  (for review  see  reference 2).  In 
experimental  animals,  particularly  inbred  mice,  it  has  been  considerably  easier  to 
demonstrate tumor-specific antigens, both by serological and cell-mediated techniques 
and to prolong survival by immunizing against these antigens (3). Despite a welter of 
publications, there are few studies in human tumor systems where the concept of tumor- 
specific antigens has been clearly established and universally confirmed. In particular, 
though  many  authors  have  demonstrated  lymphocyte-mediated cytotoxicity against 
tumor lines in both normal individuals and patients with tumors (4, 5), evidence for T- 
lymphocyte-mediated autologous tumor cytotoxicity has been very difficult to establish. 
In vitro assays of transplantation rejection using the mixed lymphocyte culture and 
cell-mediated lympholysis tests, have provided clear insight into the nature of antigenic 
determinants necessary for generation of cytotoxic T  cells. The pioneering studies of 
Eijsvoogel et al. (6) on HLA recombinant families demonstrated the need for two types of 
antigens, the first type coded for by genes closely associated with those of the HLA D 
locus cause lymphocyte activation, whereas the second class of determinants,  closely 
associated with the serologically defined HLA A, B, and C locus antigens,  acts as the 
target for the cytotoxic T lymphocytes. Eijsvoogel et al. (7) also showed that production of 
cytotoxic T lymphocytes was possible even if the lymphocyte-activating  determinant and 
serologically defined antigens were present on different cells. Zarling et al.  (8) applied 
this principal to study leukemia patients and then reported one patient where stimula- 
tion of remission lymphocytes by mitomycin C inactivated autologous myeloblasts and a 
third party inactivated allogeneic lymphocytes in short-term culture led to the production 
of cytotoxic cells against autologous blasts but not the remission lymphocytes. 
We report and confirm this observation in a  series of 14 patients with acute 
myelogenous leukemia and investigate the nature of the effector cell, the helper 
* Present address: Department of Immunology, National Institute of Medical Research, London 
N7, England. 
Present address: Department  of Oncology, Institute of Urology, London WC2, England. 
Abbreviations  used in this paper: AML, acute myelogenous leukemia; BCG, bacille Calmette- 
Gu~rin; CML, cell-mediated lympholysis; cpm, counts per minute; PBS, phosphate-buffered sa- 
line; PHA, phytohemagglutinin. 
912  THE  JOURNAL  OF  EXPERIMENTAL  MEDICINE  " VOLUME  147,  1978 S.  K.  LEE  AND  R.  T.  D.  OLIVER  913 
antigen on the third party cell, and the target antigen on the leukemia blast, 
and consider the relevance of these observations for development of rational 
immunotherapy for this disease. 
Materials and Methods 
Patients.  Criteria for the diagnosis of acute myelogenous leukemia and therapeutic protocols 
used have been reported in detail elsewhere  (9,  10). All the patients studied were in complete 
remission and received either chemoinimunotherapy  with BCG plus irradiated  allogeneic leu- 
kemic  myeloblasts  according  to  the  protocol  reported  by  Powles  et  al.  (11,  12)  or  the  same 
chemotherapy plus BCG alone (2). The leukemic myeloblasts were removed from patients at the 
time of diagnosis, using the IBM Blood Cell Separator (IBM Corp., White Plains, N.Y.) (13) and 
then frozen in liquid nitrogen using techniques reported elsewhere  (14). Before use they were 
thawed and treated with 10,000 rads in a  linear accelerator. 
Cytotoxicity Assay.  Remission lymphocytes were prepared from defibrinated peripheral blood 
using  the  Ficoll-Hypaque  technique  (Pharmacia  Fine  Chemicals,  Div.  of  Pharmacia  Inc., 
Piscataway, N.J.) and adjusted to a  concentration of 1 x  106/ml. They were set up in mixed cell 
culture with equal volumes of stimulators adjusted to the same concentration after inactivation 
with mitomycin C (25 pg/5 ×  10  ~ cells in 1 ml for 30 min at 37°C and then washed twice). After 6- 
7 days, culture in 5% CO2 and air at 37°C using RPMI 1640 medium supplemented with 4 mM 
glutamine and 10% AB serum, the cells were harvested and washed. To measure cytotoxicity 5 x 
105 primed cells were incubated with 1 x  104 '~lCr-labeled target cells (200 ~Ci/10  ~ cells incubated 
for 1 h at 37°C and washed twice) in a total volume of 0.2 ml with RPMI-1640 and 10% AB serum 
in V-shaped Cooke microtiter plates (M220).  After 4 h the plates were spun gently and the 0.1-ml 
supernate was assayed for counts per minute (cpm) 51Cr release using a gamma counter. 
Preparation  of T-  and  B-Rich  Effector  Cell  Population.  The  technique  used  was  that  of 
Greaves et al. (15) in 1974. Briefly, 200 ~l of packed sheep erythrocytes (washed twice in acetate 
buffer,  pH  5.5)  was  incubated  with  15  U  of neuraminidase  (Behring  Diagnostics,  American 
Hoechst Corp., Somerville, N.J.) for 1/2 h at 37°C. Then it was washed once in phosphate-buffered 
saline  (PBS) and resuspended in 1 ml TC199 to give a  20% cell suspension.  An equal volume of 
leukocytes separated by the Ficoll-Hypaque technique (4  x  10  ~ cells/ml) was mixed with equal 
quantities of erythrocyte suspension  together with 3 ml of TC199 and 3 ml of heat-inactivated 
fetal calf serum. The mixture was incubated for 10 min at 37°C, then spun at 1,500 rpm (300g) for 
5 min, reincubated at 4°C for 20 rain, and then the cells were gently resuspended, respun, and left 
at 4°C for 1 h.  The rosette-forming cells were separated  from nonrosetting cells after a  second 
centrifugation on Ficoll-Hypaque gradient.  The sheep erythrocytes were removed from rosette- 
forming cells by Tris ammonium chloride lysis. 
Horse  anti-human  thoracic  duct  lymphocyte  serum  was  absorbed  with  chronic  lymphatic 
leukemia  cells  (sequential  absorption  for  30  min  at  room temperature  with  cells from  three 
different patients) according to the technique of Brochier et al. (16), and then spun at 100,000g for 
1 h  at 40°C.  Chimpanzee anti-human  chronic lymphatic leukemia serum after absorption with 
pooled platelets was provided by Shroeder and Van Rood. Before testing, effector cells from a  6- 
day culture were treated with an equal volume of absorbed serum and incubated at 37°C for 30 
min, spun,  and then resuspended in an equal volume of rabbit complement diluted 1:2 in TC199. 
Incubation was continued for 1 h  at room temperature and then the cells were washed twice in 
TC199 and tested for cytotoxicity as described above. 
Results 
Table  I  summarizes  details  of cpm  data  on  results  from  14  patients  and 
shows how the spontaneous release and specific release are calculated.  When 
remission lymphocytes from the acute myelogenous leukemia  (AML) patients 
were cultured with autologous blast cells and allogeneic lymphocytes, it became 
clear that the occurrence of chromium release  was greater here than in the 
control cultures (even for the cells where the spontaneous release is quite high). 914  LEUKEMIA-SPECIFIC  T-CELL-MEDIATED  LYMPHOCYTOTOXICITY 
TABLE  I 
Summary cpm Data from Patients with AML 
Pa~ent 
51Cr release from autologous blast cells 
Spontaneous  Test*  Total* 
%  % 
M.B.  395 (14)§  1,475  (43)11  2,890 
P.W.  507 (31)  1,178 (60)  1,627 
J.R.  335 (45)  379  (11)  740 
G.P.  171  (9)  390 (12)  1,944 
J.K.  672 (33)  926  (19)  2,017 
M.S.  1,739  (36)  3,317 (51)  4,812 
I.C.  1,224 (35)  1,856 (28)  3,486 
A.T.  568 (21)  818 (10)  2,822 
T.W.  304 (25)  866  (56)  1,200 
M.F.  397  (27)  585  (17)  1,491 
,E.  B.  393 (20)  396 (0.2)  1,940 
F.H.  257 (39)  263 (6)  600 
B.R.  670 (23)  684 (1)  2,915 
E.H.  180 (30)  180 (0)  601 
* Remission  lymphocytes  primed  by  autologous  leukemic  blasts plus 
aUogeneic lymphocytes. 
$ Cell frozen and thawed  x 3. 
§ Spontaneous cpm x  100/total cpm. 
II  (Test cpm -  spontaneous cpm)  x  100/total cpm -  spontaneous cpm. 
That this release is not a  nonspecific effect of short-term culture is shown in 
Table II, which demonstrates that in those cultures where there is significant 
cytotoxicity against autologous blasts, there is not a concomitant cytotoxicity 
against the autologous ren~ission  lymphocytes. Culture of remission lympho- 
cytes alone for 6-7  days  (column 1)  produced weak cytotoxicity against the 
autologous blast cell in 3 of the 14 patients (3-6% release). Culture of remission 
lymphocytes with inactivated autologous blast cells alone  ~  (column 2) produced 
weak killing (1-8% release) in nine of the patients (median 5%). Culture with 
inactivated allogeneic lymphocytes (column 3) produced slightly greater killing 
(6-30%  release)  in  5  of the  patients  (median 8%); whereas culture  with  a 
mixture of mitomycin C-treated autologous blast cells and allogeneic lympho- 
cytes (column 4) produced killing in 11 of 14 experiments (6-60% release, with a 
median of 19%). This activity was greater in those who had been in remission 
longer than 6 mo (nine out of nine positive), compared with those in remission 
for less than 6 mo (two out of five positive).  As a measure of reproducibility, 
results from two patients tested on several occasions are shown in Table HI. 
Patient  M.  B.  had been in  remission for 36  mo and had  stopped  receiving 
maintenance chemotherapy 2 yr previously. Patient T.  W.  received his last 
course of maintenance chemotherapy after the second assay and when tested 2 
days after completing this course of treatment, had lost all reactivity. This 
gradually returned, and when tested 2 mo after chemotherapy, was greater 
than before chemotherapy. 
Fractionation Studies of Effector Cells.  Two approaches have been used to 
investigate the nature of the cell involved (Tables IV, V). In the first experi- S.  K.  LEE  AND  R.  T.  D.  OLIVER 
TABLE  II 
Specifwity Controls Anti-Leukemia Cytotoxicity Assay 
915 
Patient 
sICr  release  from au-  sICr  release  from al- 
s~Cr  release  from au- 
Time  tologous leukemia  logeneic  lympho-  tologous lymphocytes$ 
in  blasts  cytes$ 
CR* 
1  2  3  4  1  2  3  4  1  2  3  4 
mo  %  %  % 
M.B.  36  ND  6  8  43  ND  0  23  29  ND  ND  ND  ND 
P.W.  8  0  0  0  60  0  9  44  35  0  0  0  0 
J.R.  10  0  2  0  10  0  0  34  17  0  0  0  0 
G.P.  12  6  8  13  12  3  11  60  11  0  0  0  0 
J.K.  15  0  0  0  19  2  0  50  47  0  0  2  6 
M.S.  10  ND  6  ND  52  ND  0  ND  6  0  0  3  0 
I.C.  20  3  5  30  28  5  3  10  8  0  0  0  0 
A.T.  14  0  0  6  10  4  0  10  12  0  0  3  0 
T.W.  10  0  2  0  9  2  1  48  74  0  0  0  0 
M.F.  5  0  1  6  19  0  0  5  6  0  0  0  0 
E.B.  2  0  0  0  0  0  0  3  3  0  0  0  0 
F.M.  5  0  5  0  6  0  0  9  3  0  0  0  0 
B.R.  4  3  1  0  1  0  0  19  10  0  0  0  0 
E.M.  3  0  0  0  0  3  5  14  26  0  0  0  0 
* CR, Complete remission; ND, not done. 
$ Cultured with PHA  for  3 days before labeling. 
1, Culture of remission lymphocytes for 7 days, 2, culture of remission lymphocytes for 7 days 
with autologous leukemic blasts,  3, Culture of  remission lymphocytes for 7 days with allogeneic 
lymphocytes, 4, Culture  of  remission lymphocytes for  7  days  with autologous blasts  and  allogeneic 
lymphocytes. 
ments, after a 7-day culture with autologous blasts and allogeneic lymphocytes, 
the remission lymphocytes were treated with either a horse anti-human thoracic 
duct lymphocyte serum absorbed with chronic lymphatic leukemia cells, shown 
to be specific for T cells, or chimpanzee anti-human chronic lymphatic leukemia 
serum absorbed with pooled platelets and shown to be specific for B cells. In all 
three  experiments,  the  reactivity  was  lost  after  treatment with  the  anti-T 
serum, but after treatment with anti-B reactivity was unchanged in two of the 
experiments and only slightly reduced in the third (Table IV). 
In the second type of experiment, effector cells recovered from cultures of 
remission lymphocytes with Mitomycin-C, inactivated autologous blast cells 
and allogeneic lymphocytes were separated into T- and B-rich fractions using 
the neuraminidase-treated sheep erythrocyte technique described in the Mate- 
rials and Methods. The two populations were tested against autologous blasts 
and cytotoxicity could only be demonstrated in the E rosette-positive population 
(Table V). 
Nature  of Determinant  on  Third Party Allogeneic  Cell.  To compare the 
effectiveness of lymphocyte-activating determinants of the HLA D region and 
the serologically defined antigens of the HLA A, B, and C region, experiments 
were undertaken using mitomycin C-inactivated lymphoblastoid cells instead 
of allogeneic lymphocytes as third party cells in the mixed cultures. Cytotoxic 
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TABLE  HI 
Reproducibility of Autologous Leukemia Blast Cell Cytotoxicity Assay 
Primary 
mixture 
Autologous blasts as targets 
Autologous PHA transformed lym- 
phocytes as targets 
1  2  3  4  1  2  3  4 
W. W. 
M. S. 
0  0  6  13  7  13  2  4 
8  0  0  25  0  0  0  0 
ND  0  0  0  ND  3  2  3 
0  0  0  7  2  2  2  3 
ND  0  ND  6  ND  0  ND  0 
ND  ND  ND  8  ND  ND  ND  2 
ND  3  ND  10  ND  0  ND  0 
ND  11  ND  34  ND  0  ND  0 
12  3  7  118  0  0  0  0 
0  5  18  14  0  0  0  0 
ND  6  8  43  ND  ND  ND  ND 
ND  10  ND  45  ND  ND  ND  ND 
0  15  0  62  2  4  5  0 
Explanation of  columns is  the same as Table II. 
TABLE  IV 
Effect of Anti-T- and B-Cell Serum on Cell-Mediated Autologous Leukemia Cell Lysis 





Cytotoxicity*  against autologous 
leukemia blasts 
Expt. 2  Expt.  1  Expt 2.  Expt. 3 
%  % 
Untreated  100  45  51  14 
Complement alone  88  43  46  14 
Anti-CLL$  (absorbed  with  platelets  61  44  28  12 
and thymocytes) +  complement 
Anti-T  cell  (absorbed  with  CLL)  +  18  0  0  0 
complement 
* Viable effector  cell  to target  cell  ratio  50:1. 
CLL, chronic  lymphocytic leukemia. 
TABLE  V 
Effect of T- and B-Cell Separation  on Cell-Mediated  Autologous Leukemia Cell Lysis 
Treatment of  effector  cells 
E Rosette-positive  cells  in  ef- 
fector  population 
Cytotoxicity  against autolo- 
gous leukemia blasts 
1  2  1  2 
%  % 
Unfractionated  72  79  28  4 
T cells*  ND  91  27  10 
B cells*  ND  4  0  0 
* See Materials and Methods for  technique of  separation. S.  K.  LEE  AND  R.  T.  D.  OLIVER 
CELL-MEDIATED  RESPONSES AGAINST AUTOLOGOUS BLASTS 
100"  • 
917 


















autol~lous  blasts 
+  DAUDI 
f  |  o• 
Primed with  Primed with 
MOLT 4  autologous  blasts 
+ MOLT  4 
Cytotoxicity against autologous blast cell after priming with Daudi or Molt 4. 
TABLE VI 
Comparison of Allogeneic Blasts and Remission  Lymphocytes 
as Stimulators  and Targets  in CML Assay 
Target 
Allogeneic  lym- 
Stimulator  ~  phocyte 
{ Allogeneic blast 
Allogeneic lym-  Allogeneic blast 
phocyte 
%  % 
13"  11.6" 
4.1"  4.7* 
* Percentage s]Cr release is mean of four experiments. 
mixed with autologous blast cells and used to stimulate remission lymphocytes 
but  not  when  Molt  4  cells  were  mixed  with  autologous  blast  and  used  to 
stimulate  remission  lymphocytes  (Fig.  1).  Further  evidence  that  myeloid 
leukemia blasts  in general  have  a  poorer capacity  for lymphocyte  activation 
comes from comparative study of remission lymphocytes and acute myelogenous 
leukemic blast cells used as allogeneic stimulators and targets in cell-mediated 
lympholysis  assays.  Table  VI  shows,  that  as  stimulators,  myeloid  leukemia 
blast cells are considerably less effective than remission lymphocytes, whereas 
there is minimal difference in terms of the effectiveness of myeloid blast cells as 
targets for mixed lymphocyte culture-generated cytotoxic lymphocytes. 
Nature of Target Antigen on Autologous Blast Cell.  Two approaches have 
been used to study this problem. Firstly, mixing equal quantities of unlabeled 
target  cells  with 51Cr-labeled  blast  cells  showed that it was only possible to 
inhibit cytotoxicity using unlabeled autologous leukemic myeloblasts,  but not 
unlabeled phytohemagglutinin  (PHA)-transformed  remission  lymphocytes  or 918  LEUKEMIA-SPECIFIC  T-CELL-MEDIATED  LYMPHOCYTOTOXICITY 
TABLE  VII 
Cold Target Experiments 
Targets 
Exp. 
Autologous blasts  Autologous blasts  Autologous blasts  (5'Cr)  (1×10  4) + au- 
Autologous  (5'Cr)  (lx10  4)  + au-  (~'Cr)  (lx10  4) + al- 
tologous remission  blast (5'Cr)  tologous blasts  logeneic blasts 
(1 x 10  4)  (1 x 10  4)  lymphocytes  (1 X 10 4) 
(1 x 104) 
%  %  %  % 
34  5  36  31, 34, 37 
21  1  18  (23*),  19 
12  0  6  12, 18 
43  30§  41§  355§ 
611  3911  26,'II 
0¶  40¶  335.¶ 
* Cold targets =  Daudi. 
$ Cold targets =  allogeneic PHA blasts. 
§ Cold targets 1 x 103. 
II Cold targets 1 x 104. 
¶ Cold targets 4 x 104. 
TABLE  VIII 
Autologous Blasts as Targets after Priming 
Allogeneic  Allogeneic 
Patient  Autologous  Allogeneic  lymphocytes  Allogeneic  blast +  allo- 
blast  lymphocytes  +  autolo-  blast  geneic lym- 
gous blasts  phocytes 
%  %  %  %  % 
T.W.  0  0  9  0  0 
L.F.  0  0  16  0  0 
M.B.  ND  0  23  7  5 
T.W.  ND  1  51  0  0 
allogeneic leukemic myeloblasts, Daudi cells, or allogeneic lymphocytes (Table 
VII). 
Secondly, taking pairs of AML patients, stimulating remission lymphocytes 
from one patient with allogeneic blast cells from the other patient even in the 
presence of allogeneic lymphocytes from that second patient would not produce 
cytotoxic cells against autologous blasts, even though the allogeneic lympho- 
cytes from that second patient could cooperate with the autologous blasts to 
cause generation of cytotoxic cells (Table VIII). 
Indirect evidence to support the suggestion from these experiments that the 
target antigen on the autologous cell is unique for each patient, comes from 
studies using allogeneic blast cells to prime remission lymphoeytes. In a series 
of 23 experiments, using AML remission lymphoeytes primed with allogeneic 
leukemic myeloblasts,  mean specific release  from autologous blast  was  5%, 
compared to 6% mean release when allogeneic lymphocyt~s were used, 4% mean 
release when the specific autologous blast cells were used and 19% mean release 
when a mixture of autologous blasts and allogeneic lymphocytes were used for 
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To exclude the involvement of the patient's own D locus determinants known 
to be present on B cell and myeloid leukemic blast cells,  experiments were 
performed priming remission lymphocytes  with purified autologous B cells plus 
Daudi cells. No cytotoxicity was generated against the autologous blast cell. In 
addition after priming remission lymphocytes with autologous blast cells and 
allogeneic lymphocyte  or Daudi cells, effector cells with cytotoxicity against the 
specific leukemic blast cell showed no cytotoxicity against purified autologous T 
or B cells.  In a  single experiment, effector cells generated by priming with 
autologous blast plus  Daudi cells showed no cytotoxicity against autologous 
remission bone marrow. 
Discussion 
The idea of immunological stimulation by one molecule augmenting response 
to an otherwise nonimmunogenic  molecule is not new. In experimental animals, 
the use of carrier molecules to  stimulate antibody response to  haptens is  a 
standard procedure and the interdependence  of T and B cells in these responses 
is well documented (for review, see reference 17). In man, Eijsvoogel et al.  (6) 
were the first to demonstrate the interaction between the two molecules that 
was necessary for the generation of cytotoxic T  cells against transplantation 
antigens. He also showed that it was not necessary for the HLA D lymphocyte- 
activating determinant to be on the same cell as the HLA A,  B,  or C target 
antigen (7). After this, Schendell and Bach (18) were able to demonstrate the 
same principal in mice and, more recently, Zarling et al. (8) took this principal 
and applied it to study response of leukemic patients to their own blast cells. 
They showed that remission lymphocytes cultured with autologous blasts and 
allogeneic  lymphocytes generated  cytotoxic ,cells  reacting  with  autologous 
leukemic blasts in one out of six patients studied. Sondell et al.  (19) showed 
that lymphocytes from siblings HLA identical with patients with acute leuke- 
mia  could  also  respond to  patient's  blasts  and  allogeneic lymphocytes and 
generate cytotoxic cells in three out of four patients tested. 
Our data confirms these observations in a  larger series of patients but,  in 
addition,  has  investigated in greater depth the underlying mechanism. The 
studies using Daudi, a lymphoblastoid cell line which has lost all evidence of 
HLA A, B,  and C locus antigens but retains HLA D locus antigens (20) and 
Molt 4,  a  leukemia cell  line which has  no detectable HLA  D  antigens but 
readily demonstrable HLA A and B locus antigens (21) would suggest that, as 
in the response against transplantation antigens in  allogeneic cell-mediated 
lympholysis (CML), the HLA D region stimulus is what is lacking from cultures 
stimulated by autologous blast cells alone. 
The evidence from Table V that even as stimulators of allogeneic CML, blast 
cells are  deficient of HLA  D-associated lymphocyte-activating determinants 
compared to normal peripheral blood cells is in contrast to the relative ease 
with which HLA D-associated serologically defined antigens (formerly known 
as 'Ia' like, now designated as DR i.e.  D related) have been demonstrated on 
AML blasts (22). Further investigation of this observation may provide impor- 
tant evidence to help resolve the controversy of whether the two techniques are 
defining the same antigenic determinant. The lack of cytotoxicity of primed 
remission lymphocytes against autologous B cells excludes the possibility that 920  LEUKEMIA-SPECIFIC  T-CELL-MEDIATED  LYMPHOCYTOTOXICITY 
the  target  antigen  on  the  leukemic blast  is  a  normal B-cell  antigen  which 
Opelz et al.  (23) have suggested may be the cause of autologous stimulation of 
T cells by B cells. 
Though there are many studies in the literature on cytotoxic cells against 
human tumors, with the exception the study of Jondal et al.  (24) on a  single 
patient  with  Burkitt's  lymphoma,  none  of these  systems have been clearly 
demonstrated to be mediated by T  cells. The observations reported here are 
very important because of the significant role T cells have been shown to have 
in tumor rejection in experimental animals (for review see reference 25). 
Three approaches reported in this paper (cold target inhibition experiments, 
failure to generate cytotoxicity with allogeneic blast cells,  and the crossover 
experiments with pairs of patients) suggest that the target antigenic determi- 
nant on the patient's blast cell is unique for that patient's blast. Obviously, only 
by testing an extremely large panel of allogeneic lymphocytes and blast cells 
would it be possible to exclude that there is any HLA restriction influencing the 
target antigen as reported for mouse cytotoxicity reactions (26). Likewise, only 
extensive cross-testing will enable one to exclude that the target antigen is an 
altered  normal  transplantation  antigen  as  has  been  found  for  some  tumor 
antigens in the mouse (27). 
In spite of the need for more information on these points, the observation is 
important from two points of view.  First,  from the theoretical point of view, 
most experimental animals' tumors with a viral etiology have common tumor- 
specific antigens, whereas unique determinants are more usually found in non- 
virally induced tumors  (26,  29). Although this is not proof of the etiology of 
leukemia as the target could possibly be HLA restricted, the failure to isolate 
infectious viruses from human leukemias using the techniques which easily 
detect viruses in animal tumors is increasingly raising doubts about the role of 
viruses  in  the  pathogenesis  of human  leukemia.  This  viewpoint  has  been 
supported by the failure of Ihle et al. (30, 31) to find evidence of viral expression 
in the majority of radiation-induced lymphomas in C57B1/6  mice. 
Secondly, from the practical viewpoint of clinical studies of immunotherapy, 
the demonstration of a unique antigenic determinant on the patient's blast cell 
raises doubts as to the value of using allogeneic blast cells for immunotherapy 
in this disease.  So far,  in a  study comparing BCG with BCG and allogeneic 
blast  cells in  patients  with AML,  we have found no difference in  remission 
lengths or survival of our patients (2). Clearly it will be important to see if the 
principals which have been developed from our in vitro studies can be applied 
in vivo using an animal model before using this approach in clinical studies. In 
the meantime it is important that the failure of current studies of immunother- 
apy in  man to  lead to  an increase in  the long-term cure of patients  should 
not lead to the conclusion that active specific immunotherapy is of no benefit. 
The studies reported here would suggest that it has not so far been adequately 
tested. 
Summary 
Short-term culture of acute myelogenous leukemia patient's remission lym- 
phocytes  with  inactivated  autologous  leukemic  blast  cells  plus  allogeneic S.  K.  LEE  AND  R.  T.  D.  OLIVER  921 
lymphocytes,  generated  effector T  lymphocytes which  were  cytotoxic for the 
specific autologous blast  cell in  11 of 14 patients  studied.  Experiments using 
Daudi and Molt 4 lymphoblastoid cell lines as a  third-party helper cell suggest 
that an HLA D  locus incompatability is necessary to provide effective help in 
this system. Cold target inhibition experiments, crossover studies between pairs 
of patients,  and  experiments with allogeneic leukemic blast cells as priming 
stimulus  suggest  that  the  target  antigen  is  only  present  on  the  specific 
autologous blast cell. 
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